Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/11/2010US20100062003 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
03/11/2010US20100062000 Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
03/11/2010US20100061999 Antihuman tnf-alpha antibody activity lowering inhibitor
03/11/2010US20100061995 Immunotherapy To Treat Or Prevent Viral Infection
03/11/2010US20100061994 Medical uses of 39-desmethoxyrapamycin and analogues thereof
03/11/2010US20100061991 Identification of therapeutic agents for HIV infection
03/11/2010US20100061989 Method of treatment and prophylaxis
03/11/2010US20100061984 Compositions and methods for modulation of suppressor t cell activation
03/11/2010US20100061982 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
03/11/2010US20100061981 p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
03/11/2010US20100061978 Methods for detecting and treating cancer
03/11/2010US20100061976 Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
03/11/2010US20100061975 Uses for 4,17B-dihydroxyandrost-4-ene-3-one
03/11/2010US20100061974 Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
03/11/2010US20100061973 Graded Expression of Snail as Marker of Cancer Development and DNA Damage-Based Diseases
03/11/2010US20100061968 Reducing Cholesterol Levels with Combined Use of Quercetin and Statin
03/11/2010US20100061960 Amido Anti-Viral Compounds, Compositions, And Methods Of Use
03/11/2010US20100061959 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning
03/11/2010US20100061957 Hpv-16-based papillomavirus vaccines
03/11/2010US20100061935 Methods of using sustained release aminopyridine compositions
03/11/2010US20100061932 Peptides useful as cell-penetrating peptides
03/11/2010DE202009016374U1 Formulierung für Frauen im Klimakterium, in der chirurgisch bedingten Menopause oder während einer GnRH-Behandlung Formulation for women in menopause, surgically induced menopause in or during GnRH treatment
03/11/2010DE102008051572A1 Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder Preparation of phosphate binders and phosphate binders thus prepared
03/11/2010DE102008046650A1 Quetiapin enthaltende Retardtablette Quetiapine extended release tablet containing
03/11/2010DE102008046610A1 Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt Use of a pharmaceutical composition for local infection therapy and medical device
03/11/2010DE102008045854A1 Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung Particles of ziprasidone and a disintegrant containing pharmaceutical composition
03/11/2010CA2739209A1 Use of 3,11b-cis-dihydrobenazine in the treatment of dementia and associated cognitive deficit
03/11/2010CA2739201A1 Pharmaceutical compounds
03/11/2010CA2739199A1 Dihydrotetrabenazine for treatment of asthma
03/11/2010CA2738231A1 Novel choline cocrystal of epalrestat
03/11/2010CA2736767A1 N-sulfonamido polycyclic pyrazolyl compounds
03/11/2010CA2736746A1 Sn-2 myristate-containing edible oil
03/11/2010CA2736314A1 Periostin-induced pancreatic regeneration
03/11/2010CA2736306A1 Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors
03/11/2010CA2736304A1 Pyrazolopyrimidines and their use for the treatment of cns disorders
03/11/2010CA2736281A1 Tri-substituted pyrimidine compounds and their use as pde10 inhibitors
03/11/2010CA2736275A1 Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl
03/11/2010CA2736237A1 Pharmaceutical composition of a radioiodinated benzamide derivative and methods of making the same
03/11/2010CA2736229A1 Sulfur-linked compounds for treating opthalmic diseases and disorders
03/11/2010CA2736119A1 Chewable sustained release formulations
03/11/2010CA2736117A1 Compounds, compositions and methods of using same for modulating uric acid levels
03/11/2010CA2736114A1 Treatment of neurological disorders using huperzine
03/11/2010CA2736091A1 2-oxo-1,2-dihydro-quinoline modulators of immune function
03/11/2010CA2736030A1 Method of inducing an anti-viral immune response
03/11/2010CA2735970A1 Isatin derivatives for use as in vivo imaging agents
03/11/2010CA2735934A1 Method of treatment of attention deficit/hyperactivity disorder (adhd)
03/11/2010CA2735926A1 Pharmaceutical composition for use in treating sexually transmitted infections
03/11/2010CA2735913A1 A method for combating adverse effects arising from antipsychotic treatment
03/11/2010CA2735875A1 Use of quinazoline derivatives for the treatment of viral diseases
03/11/2010CA2735860A1 Synthetic methods and derivatives of triphosphate oligonucleotides
03/11/2010CA2735859A1 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
03/11/2010CA2735857A1 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
03/11/2010CA2735855A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and paracetamol
03/11/2010CA2735842A1 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
03/11/2010CA2735828A1 Substituted-(naphthalen-1-yl)-1h-imidazoles and their use for modulating uric acid levels
03/11/2010CA2735826A1 Reducing cholesterol levels with combined use of quercetin and statin
03/11/2010CA2735825A1 Hair growth promoting agent containing 15,15-difluoroprostaglandin f2.alpha. derivative as active ingredient
03/11/2010CA2735823A1 Use of a truncated eif-5a1 polynucleotide to induce apoptosis in cancer cells
03/11/2010CA2735821A1 Monocyclic amide cgrp receptor antagonists
03/11/2010CA2735811A1 Compositions and methods for inhibiting entry of a hepatic virus
03/11/2010CA2735806A1 Aminotriazolopyridines and their use as kinase inhibitors
03/11/2010CA2735795A1 Novel inhibitors
03/11/2010CA2735794A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
03/11/2010CA2735783A1 Nucleoside derivatives as inhibitors of viral polymerases
03/11/2010CA2735782A1 Heterocyclic pim-kinase inhibitors
03/11/2010CA2735779A1 Bicyclic kinase inhibitors
03/11/2010CA2735775A1 6-substituted benzoxazines
03/11/2010CA2735773A1 Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
03/11/2010CA2735770A1 7-(piperazine-1-ymethyl)-1h-indole-2-carboxylic acid (phenyl)-amide derivatives and allied compounds as p38 map kinase inhibitors for the treatment of respiratory diseases
03/11/2010CA2735764A1 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
03/11/2010CA2735722A1 Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
03/11/2010CA2735714A1 Treatment of neonate foals with meloxicam
03/11/2010CA2735709A1 Agent for treating myelofibrosis
03/11/2010CA2735653A1 Method of treating atrial fibrillation
03/11/2010CA2735593A1 Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
03/11/2010CA2735521A1 Indolizine inhibitors of leukotriene production
03/11/2010CA2735420A1 Macrocyclic pyrimidines as protein kinase inhibitors
03/11/2010CA2735229A1 Combination therapy for tuberculosis
03/11/2010CA2735208A1 Novel benzamides, production thereof, and use thereof as medicaments
03/11/2010CA2735139A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid
03/11/2010CA2735008A1 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor
03/11/2010CA2734691A1 Method for making cetirizine tablets
03/11/2010CA2734682A1 Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8
03/11/2010CA2734527A1 Novel compounds as cannabinoid receptor ligands
03/11/2010CA2734523A1 Methods and compositions for the treatment of cancer
03/11/2010CA2734500A1 Compounds that modulate intracellular calcium
03/11/2010CA2734415A1 Picolinamide derivatives as kinase inhibitors
03/11/2010CA2734392A1 Organic compounds
03/11/2010CA2734125A1 Platinum complex and medical compound containing same
03/11/2010CA2733709A1 5-substituted benzoxazines
03/11/2010CA2733671A1 Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
03/11/2010CA2733533A1 Hedgehog pathway modulators
03/11/2010CA2732338A1 Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen
03/10/2010EP2161280A2 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications
03/10/2010EP2161275A1 Prodrugs of 2,4-pyrimidinediamine compounds and their uses
03/10/2010EP2161273A1 Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
03/10/2010EP2161271A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
03/10/2010EP2161268A1 Carbacephem beta-lactam compounds for the treatment of bacterial infections
03/10/2010EP2161266A1 Benzofuran derivatives as orexin receptor antagonists
03/10/2010EP2161265A2 Compounds having selective inhibiting effect at GSK3
1 ... 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 ... 7860